<DOC>
	<DOCNO>NCT00737477</DOCNO>
	<brief_summary>This single-arm study ass efficacy safety monthly administration SC Mircera maintenance hemoglobin level participant chronic kidney disease peritoneal dialysis . Participants currently receive maintenance treatment SC erythropoietin stimulate agent ( ESAs ) receive monthly SC injection Mircera , start dose derive last weekly ESA receiving .</brief_summary>
	<brief_title>A Study Monthly Subcutaneous ( SC ) Mircera Maintenance Treatment Participants With Chronic Kidney Disease Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adults great equal ( ≥ ) 18 year age Chronic kidney diseaserelated anemia peritoneal dialysis ≥3 month Continuous SC maintenance stable ESA therapy 4 week prior study start Transfusion red blood cell previous 8 week Poorly control hypertension require interruption ESA treatment previous 6 month Significant acute chronic bleed previous 8 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>